The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Tumour lysis syndrome: new therapeutic strategies and classification
Abstract
Summary: Tumour lysis syndrome (TLS) describes the metabolic derangements that occur with tumour breakdown following the initiation of cytotoxic therapy. TLS results from the rapid destruction of malignant cells and the abrupt release of intracellular ions, nucleic acids, proteins and their metabolites into the extracellular space. These metabolites can overwhelm the body's normal homeostatic mechanisms and cause hyperuricaemia, hyperkalaemia, hyperphosphaetemia, hypocalcaemia and uraemia. TLS can lead to acute renal failure and can be life‐threatening. Early recognition of patients at risk and initiation of therapy for TLS is essential. There is a high incidence of TLS in tumours with high proliferative rates and tumour burden such as acute lymphoblastic leukaemia and Burkitt's lymphoma. The mainstays of TLS prophylaxis and treatment include aggressive hydration and diuresis, control of hyperuricaemia with allopurinol prophylaxis and rasburicase treatment, and vigilant monitoring of electrolyte abnormalities. Urine alkalinization remains controversial. Unfortunately, there have been few comprehensive reviews on this important subject. In this review, we describe the incidence, pathophysiological mechanisms of TLS and risk factors for its development. We summarise recent advances in the management of TLS and provide a new classification system and recommendations for prophylaxis and/or treatment based on this classification scheme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Self-citationCohen, L. F., Balow, J. E., MAGRATH, I. T., Poplack, D. G., & Ziegler, J. L. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90286-7 · Cited by 431
Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.697 · Cited by 361
Cell kinetics and chemotherapy: a critical review.
Tannock, I. F. (1978) · PubMed · Cited by 223
The Effectiveness of the Xanthine Oxidase Inhibitor Allopurinol in the Treatment of Gout
KLINENBERG, J. R., GOLDFINGER, S. E., & SEEGMILLER, J. E. (1965) · Annals of Internal Medicine · doi:10.7326/0003-4819-62-4-639 · Cited by 214
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies
Pui, C.-H., Relling, M., Lascombes, F., Harrison, P., Struxiano, A., Mondesir, J.-M., Ribeiro, R., Sandlund, J., Rivera, G., Evans, W., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400850 · Cited by 174
Biochemistry of Uric Acid and Its Relation to Gout
Seegmiller, J. E., Laster, L., & Howell, R. R. (1963) · New England Journal of Medicine · doi:10.1056/nejm196303282681306 · Cited by 168
Jeha, S. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90037-x · Cited by 161
Prevention of Hyperuricemia in Leukemia and Lymphoma
Krakoff, I. H. (1965) · JAMA · doi:10.1001/jama.1965.03090010007001 · Cited by 140
Allopurinol: Intravenous Use for Prevention and Treatment of Hyperuricemia
Smalley, R. V., Guaspari, A., Haase-Statz, S., Anderson, S. A., Cederberg, D., & Hohneker, J. A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1758 · Cited by 107
Cited by
Howard, S. C., Jones, D. P., & Pui, C.-H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0904569 · Cited by 1,044
Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00010 · Cited by 434
The multiple roles of LDH in cancer
Claps, G., Faouzi, S., Quidville, V., Chehade, F., Shen, S., Vagner, S., & Robert, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00686-2 · Cited by 351
Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
Xu, X.-J., & Tang, Y.-M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.004 · Cited by 156
Metadata
- Authors
- Cairo, M. S., & Bishop, M.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2004-07-22
- Volume
- 127
- Issue
- 1
- Pages
- 3-11
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2134138207
- Cited by
- 1,076
- References
- 16
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumour lysis syndrome: new therapeutic strategies and classification. https://app.cochat.ai/papers/10.1111/j.1365-2141.2004.05094.x
- The paper
- Cairo, M. S., & Bishop, M. (2004). Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2004.05094.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
